Shortage of alteplase and tenecteplase injections

Date of issue: 3-Aug-22
Reference no: NatPSA/2022/006/DHSC

This alert is for action by: All organisations using alteplase and tenecteplase injections

This is a safety critical and complex National Patient Safety Alert. Implementation should be co-ordinated by an executive lead (or equivalent role in organisations without executive boards) and supported by the Pharmacy department and clinical leaders in stroke medicine, respiratory medicine, renal, cardiology, and emergency medicine.

Explanation of identified safety issue:
There will be supply constraints facing alteplase (Actilyse®) 10mg, 20mg and 50mg injections for the remainder of 2022. Tenecteplase (Metalyse®) 10,000unit injections will go out of stock in the coming months. At present the situation is expected to improve in early 2023.

Alteplase is licensed for thrombolytic treatment of acute ischaemic stroke, acute myocardial infarction (MI) and acute massive pulmonary embolism (PE) with haemodynamic instability. Tenecteplase is licensed for the management of acute MI.

Boehringer Ingelheim is the sole supplier of both these products in the UK. There are manufacturing constraints causing global issues with the supply of these products.

Availability of stock
Boehringer Ingelheim has put restrictions in place for alteplase injection to conserve supplies until further stock is available. Trusts will have access to:
- Alteplase 50mg – approximately normal demand
- Alteplase 20mg – approximately half of normal demand
- Alteplase 10mg – approximately two thirds of normal demand

Demand is calculated at trust level based on historical orders and stock available in trusts and will be coordinated by Boehringer Ingelheim and the Regional Pharmacy Procurement Specialists.

Boehringer Ingelheim has also put restrictions in place for tenecteplase to ensure stock is not depleted earlier than anticipated.

Actions required
Actions to be completed by 10/08/2022

1. Assess stock holding of alteplase and tenecteplase injections to ensure current stock levels are correctly recorded in pharmacy systems.
2. Centralise stock in pharmacy where appropriate to do so.
3. Alteplase stock should be conserved for patients with acute ischaemic stroke, given the lack of an alternative and the significant risk of harm without receipt of treatment.
4. Consider the feasibility of alternative therapeutic options to alteplase and tenecteplase where they exist.
5. Reduce wastage by selecting appropriate vial sizes and using the most appropriate doses, giving consideration to rounding down to the nearest whole vial.
6. Pharmacy staff should order alteplase injections in line with their allocations and order tenecteplase injection in line with historic order patterns; unusual orders will be challenged.
7. Pharmacy staff should liaise with their Regional Pharmacy Procurement Specialist to manage allocated stocks of alteplase. Ensuring proactive stock management and prompt liaison should stock levels become critically low.
Additional information:

**Alternative thrombolytic treatments**

**Stroke**  
Only alteplase is licensed for the treatment of ischaemic stroke. Stroke teams may also have experience of using tenecteplase from participation in clinical trials, though this would be an unlicensed use. Mechanical thrombectomy is also used to treat some patients with acute ischaemic stroke but should be used in conjunction with alteplase in the majority of patients. There are no other therapeutic options for the treatment of acute ischaemic stroke.

**Myocardial Infarction and dissolution of thrombi and emboli**

**Streptokinase**  
- The 1,500,000 IU strength is licensed for the treatment of acute MI within 12 hours of onset with persistent ST-segment elevation or recent left bundle-branch block.
- The 250,000 and 750,000 IU strengths are licensed for intravascular dissolution of thrombi and emboli in: acute massive pulmonary embolism, acute, sub-acute or chronic (not older than 6 weeks) occlusion of peripheral arteries, extensive deep vein thrombosis, and central retinal venous or arterial thrombosis (arterial occlusions not older than 8 hours, venous occlusions not older than 10 days).

Repeat treatment with streptokinase administered more than 5 days and less than 12 months after initial treatment may not be effective due to increased likelihood of resistance as a result of antistreptokinase antibodies. Also, the therapeutic effect may be reduced in patients with recent streptococcal infections such as streptococcal pharyngitis, acute rheumatic fever and acute glomerulonephritis.

**Urokinase**  
Urokinase is licensed for:
- thrombosed intravascular catheters and cannulae,
- extensive acute proximal deep vein thrombosis,
- acute massive pulmonary embolism, and
- acute occlusive peripheral arterial disease with limb threatening ischaemia

Supplies of urokinase 10,000 units and 25,000 units are not available however, urokinase 100,000 units is meeting demand and can support a small increase in use; please refer to the Medicine Supply Notification which includes link to Dear HCP letter regarding dilution of this high strength product.

**Off label uses**  
For the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis; please refer to Medicine Supply Notification the issued for the shortage of alteplase (Actilyse Cathflo®) 2mg powder for solution for injection vials. For paediatric use, alteplase should only be used as rescue therapy to preserve vascular access in children on haemodialysis when other agents have been ineffective. For prophylaxis of central venous line occlusion in paediatrics, alteplase should only be used for the highest risk patients i.e. infants and small children.

For other off label uses, discuss locally with the relevant specialist noting the advice contained within this alert.

**References**  
- SmPC alteplase: NICE guideline for stroke and transient ischaemic attack in over 16s: diagnosis and initial management
- SmPC tenecteplase: NICE guidelines for management of acute coronary syndromes
- SmPC streptokinase: NICE guideline for the diagnosis and management of atrial fibrillation
- SmPC urokinase

**Stakeholder engagement**  
The following stakeholders have been engaged in the management and consulted in the drafting of this alert: Specialist Pharmacy Service Medicines Information, Medicine Shortage Response Group, NHS England National Clinical Directors for stroke, heart disease and respiratory, and specialist renal clinicians.

**Advice for Central Alerting System (CAS) officers and risk managers**  
This is a safety critical and complex National Patient Safety Alert. In response to [CHT/2019/001](https://improvement.nhs.uk/resources/national-patient-safety-alerting-committee/) your organisation should have developed new processes to ensure appropriate oversight and co-ordination of all National Patient Safety Alerts. CAS officers should send this Alert to the executive lead nominated in their new process to coordinate implementation of safety critical and complex National Patient Safety Alerts, copying in the leads identified on page 1.